Use of parthenolide to inhibit cancer

Details Use of parthenolide to inhibit cancer Use of parthenolide to inhibit cancer

2005-05-10

2005-05-10

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S449000, C514S510000, C514S468000, C424S464000

Reexamination Certificate

active

06890946

ABSTRACT:
The invention provides a method comprising the use of parthenolide, including its analogs, to treat cancer or conditions characterized by abnormal angiogenesis.

REFERENCES:
patent: 5514555 (1996-05-01), Springer et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: WO 9622774 (1996-08-01), None
patent: WO-9933463 (1999-07-01), None
Hehner et al., Sesquiterpene Lactones Specifically Inhibit Activation of NF-RB by Preventing the Degradation of IRB-I and IRB-J. The Journal of Biological Chemistry, vol. 273, No. 3, Jan. 16, 1998, pp. 1288-1297.*
Bork, P..M. ,et al. ,“Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kB”,FEBS Lett., vol. 402,No. 1, Database Derwent Drug file on STN, Derwent Information Limited, No. 1997-09449, (1997),85-90.
Hehner, Steffen.P. ,et al. ,“Sesquiterpene lactones specifically inhibit activation of NF-kB by preventing the degradation of lkB-alpha and lkB-beta”,J. Biol. Chem., vol. 273, No. 3, Database Chemical Abstracts on STN, American Chemical Society, No. 128:200703, (1998), 1288-1297 CTO Oct. 20, 2003.
Hehner, Steffen.P. ,et al. ,“The antiInflammatory Sesquiterpene lactone parthenolide inhibits NF-kB by targeting the lkB kinase complex”,J. immunol. vol. 163, No. 10, Database Chemical Abstracts on STN, American Chemical Society No. 132:44670, (1999),5617-5623.
Hwang, Daniel.,et al. ,“Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases”,Biochem., Biophys. Res. Commun., vol. 226, No. 3, Database Chemical Abstracts on STN, American Chemical Society, No. 125:273221, (1996),810-818.
Ross, Jonathan.J. ,et al. ,“Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion”,Planta Med., vol. 65, No. 2, Database Chemical Abstracts on STN, American Chemical Society, No. 120:232122, (1999),126-129.
Wiedhopf, R..M. ,et al. ,“Tumor inhibitory agent fromMagnolia grandiflora(Magnoliaceae) 1. Parthenolide”,J. Pharm. Sci., vol. 62, No. 2, Database Chemical Abstracts on STN, American Chemical Society, No. 78:115152, (1973),345.
Woynarowski, Jan.M. ,et al. ,“Inhibitors of DNA biosynthesis in HeLa cells by cytotoxic antitumor sesquiterpene lactones”,Mol. PHaarmacol., vol. 19, No. 1, Database Chemical Abstracts on STN, American Chemical Society, No. 94:150059, (1981),97-102.
Baldwin, et al., “The NF-kB and lkB Proteins: New Discoveries and Insights”,Annual Review of Immunology, 14 ISSN: 0732-0582, (1996),649-683.
Iruela-Arispe, M. L., et al., “Angiogenesis: A Dynamic balance of Stimulators and Inhibitors”,Thrombosis and Haemostasis, 78(1)ISSN: 0340-6245, (1997),672-677.
Jain, N. K., et al., “Antinociceptive and anti-inflammatory effects ofTanacetum partheniumL. extract in mice and rats”,Journal of Ethnopharmacology, 68(1-3)ISSN: 0378-8741, (1999),251-259.
Mondranondra, I. O., et al., “Sesquiterpene Lactones and other constituents from a Cytotoxic Extract of Michelia-Floribunda”,Pharmaceuticat Research, 7,(12)ISSN: 0724-8741, (1990),1269-1272.
Patel, N. M., et al., “Paclitaxel Sensitivity of Breast Cancer Cells with Constitutively active NF-KappaB is enchanged by IkappaBalpha super-repressor and parthenolide”,Oncogene, 19(36)ISSN: 0950-9232, (Aug. 24, 2000),4159-4169.
Robles, M. , et al., “Recent studies on the Zoopharmacognosy, Pharmacology and Neurotoxicology of Sesquiterpene Lactones”,Planta Medica, 61(3)ISSN: 0032-0943, (1995),199-203.
Sharma, H. W., et al., “The NF-Kappab Transcription Factor in Oncogenesis”,Anticancer Research, Helenic anticancer Institute, 16 ISSN: 0250-7005, (Mar. 1996),589-596.
Yoshida et al., “Suppression of Retinal Neovascularization by the NF-αB Inhibitor Pyrrolidine Dithiocarbamate in Mice”,Investigative Ophthalmology & Visual Science, 40, 1624-1629 (1999).

Affiliated with

Also associated with

Rating

Use of parthenolide to inhibit cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of parthenolide to inhibit cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of parthenolide to inhibit cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3416400